Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

NCT03250624 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: CD5024 0.3% cream
DRUG: Placebo

Sponsor

Galderma R&D